ERBB2 and breast cancer: A total of 390 BC patients with mammographically visible lesions were enrolled for analysis, stratified by molecular subtype as follows: Luminal A (n=102), Luminal B (n=155), HER2-positive/HR-positive (n=54), HER2-positive/HR-negative (n=27), and TN (n=52).